secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001171843-25-000493
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B
--------------------------------------------------------------------------------

- FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.
- Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.
- Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.
- Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).
- FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/0001171843-25-000493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/f8k_012925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer